Form Type:  CT ORDER
Filing Date:  3/13/2018 
CIK:  0001348911 
BUILDING 200, STE. 2203
City, State, Zip:  CAMBRIDGE, Massachusetts 02139 
Telephone:  (857) 999-0075 
Fiscal Year:  04/30 
Last Trade
Last Trade: 
1.75 (8.93%)  
Trade Time: 
Feb 15  
Market Cap: 
Trade KALV now with 

© 2019  
Description of Business
We are a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Our first product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema ("HAE") and diabetic macular edema ("DME"). We apply our insights into the chemistry of proteases and, with our current programs, the biology of the plasma kallikrein system, to develop small molecule inhibitors with high selectivity, potency and bioavailability that we believe will make them successful treatments for disease. We have created a structurally diverse portfolio of oral plasma kallikrein inhibitors and advanced multiple drug candidates into Phase 1 clinical trials for HAE in order to create what we believe will be best-in-class oral therapies.
Register and access this filing in: